亚宝药业太原制药有限公司

What 亚宝药业太原制药有限公司 does

亚宝药业太原制药有限公司 (Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd.) is a Chinese pharmaceutical entity registered in Taiyuan, Shanxi Province. Its corporate name indicates it is a member of the Yabao (亚宝) pharmaceutical group, and given the legal-name pattern ("Taiyuan Pharmaceutical Co., Ltd."), it most plausibly operates as a regional manufacturing, processing, or specialized dosage-form production site serving either the Yabao parent group's product portfolio or third-party customers. The company employs 37 staff according to the firmographic record, which is consistent with a single-site production facility rather than a commercial-stage pharma brand with national sales operations. No product list, manufacturing certifications, GMP registration status, regulatory approvals, customer accounts, pricing model, or distribution channels are disclosed in the available source data.

Business model mechanics are not visible in the input: there is no disclosed revenue figure, no pricing model, no customer segment breakdown, no go-to-motion detail, and no technology stack disclosure. The most plausible business model is either captive contract manufacturing for the Yabao group (revenue realized via intercompany transfer pricing) or toll/contract manufacturing for external pharma customers in the Shanxi and northern China region. A notable data integrity issue is that the company's listed website (https://yabaoty.com/) resolves to "星空体育" (Star Sports), a sports betting platform described as a "World Cup official cooperation platform," which is unrelated to pharmaceutical operations; this suggests either a dormant, expired, or hijacked domain, or a data attribution error in the source record.

No technology, proprietary features, AI capabilities, integrations, partnerships, leadership team, M&A activity, funding rounds, regulatory actions, or strategic moves are documented in the input data. As a result, the analytical picture is limited to firmographic basics (name, location, 37 employees), and any deeper assessment of competitive position, growth direction, or investment merit requires additional primary-source verification.

Name

亚宝药业太原制药有限公司

Legal name

亚宝药业太原制药有限公司

Website

https://yabaoty.com

Company type

Private

Headcount range

11–50 employees

Short description

Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. (亚宝药业太原制药有限公司) is a 37-employee pharmaceutical entity in Taiyuan, Shanxi Province, China, appearing to operate as a regional manufacturing site within the broader Yabao (亚宝) pharmaceutical group.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Pharmaceutical manufacturing
• Generic drug production
• Medicinal products
• Drug formulation
• Finished pharmaceuticals

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Others

Core offering

亚宝药业太原制药有限公司 is, by its registered name, a pharmaceutical manufacturing company (制药有限公司) based in Taiyuan, Shanxi Province, China, with approximately 37 employees. The specific product portfolio, dosage forms, therapeutic categories, and manufacturing scope are not documented in the available source material.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Apeloa Pharmaceutical Co., Ltd. A Chinese generic finished-dose manufacturer with broad therapeutic coverage and API-to-formulation integration. Highly comparable in business model and end markets to a small Chinese generic FDF manufacturer.
• Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. Subsidiary of Apeloa focused on finished dosage generic manufacturing. Directly comparable in scale and product mix to a small Chinese generic FDF producer.

Broad incumbents

• CSPC Pharmaceutical Group Ltd. Large Hong Kong-listed Chinese pharmaceutical manufacturer with significant generic finished-dose operations. Comparable therapeutic categories and Chinese hospital channel, though much larger scale.
• Zhejiang Huahai Pharmaceutical Co., Ltd. China-based pharmaceutical manufacturer with both API production and finished generic formulations, including cardiovascular and CNS therapies. Comparable generic FDF business model with international reach.
• Yabao Pharmaceutical Group Co., Ltd. The parent group implied by the company's name. Yabao is a major Shanxi-based generic pharmaceutical group with a broad portfolio of finished-dose generics, providing the most direct comparability for scale, geography, and therapeutic focus.
• Livzon Pharmaceutical Group Inc. Diversified Chinese pharmaceutical company with chemical drug, API, and finished-dose operations. Comparable as a domestic generic and specialty pharma peer serving Chinese hospital and retail channels.
• Northeast Pharmaceutical Group Co., Ltd. One of China's largest state-owned generic pharmaceutical manufacturers, producing APIs and finished dosage forms. Comparable as a domestic generic pharma peer, though substantially larger.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/%E4%BA%9A%E5%AE%9D%E8%8D%AF%E4%B8%9A%E5%A4%AA%E5%8E%9F%E5%88%B6%E8%8D%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 亚宝药业太原制药有限公司